Overview

• Preclinical studies show that the senolytic drugs o-Vanillin and RG-7112 effectively clear senescent cells, reduce inflammation, and repair spinal damage in mice.
• The combination of o-Vanillin, a turmeric-derived compound, and RG-7112, an FDA-approved cancer drug, demonstrated the greatest therapeutic impact when used together.
• Researchers were surprised that oral administration allowed the drugs to reach spinal disks, which are notoriously difficult to target with treatments.
• The study provides the first evidence of o-Vanillin’s ability to remove senescent cells, with researchers now working to optimize its pharmacokinetics for longer-lasting effects.
• The team is preparing to translate these findings into human clinical trials, aiming to address the root causes of chronic low back pain and potentially other age-related conditions.